CN111686208A - 具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 - Google Patents
具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN111686208A CN111686208A CN202010569690.8A CN202010569690A CN111686208A CN 111686208 A CN111686208 A CN 111686208A CN 202010569690 A CN202010569690 A CN 202010569690A CN 111686208 A CN111686208 A CN 111686208A
- Authority
- CN
- China
- Prior art keywords
- parts
- blue light
- medicine
- retina
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 235000013305 food Nutrition 0.000 title claims abstract description 43
- 230000006378 damage Effects 0.000 title claims abstract description 42
- 210000001525 retina Anatomy 0.000 title claims abstract description 41
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 28
- 208000014674 injury Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title abstract description 17
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 26
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 14
- 235000012680 lutein Nutrition 0.000 claims abstract description 13
- 229960005375 lutein Drugs 0.000 claims abstract description 13
- 239000001656 lutein Substances 0.000 claims abstract description 13
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 13
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 13
- 229960003080 taurine Drugs 0.000 claims abstract description 13
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 13
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 12
- 241000237502 Ostreidae Species 0.000 claims abstract description 12
- 235000020636 oyster Nutrition 0.000 claims abstract description 12
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 11
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 210000000582 semen Anatomy 0.000 claims abstract description 10
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 9
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 9
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 9
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 9
- 230000036541 health Effects 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 241000723353 Chrysanthemum Species 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 5
- 230000009977 dual effect Effects 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims 1
- 208000003464 asthenopia Diseases 0.000 abstract description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 43
- 241000700159 Rattus Species 0.000 description 40
- 230000000694 effects Effects 0.000 description 33
- 230000002207 retinal effect Effects 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 18
- 210000001508 eye Anatomy 0.000 description 16
- 239000000463 material Substances 0.000 description 12
- 239000003642 reactive oxygen metabolite Substances 0.000 description 12
- 102000016938 Catalase Human genes 0.000 description 11
- 108010053835 Catalase Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000004438 eyesight Effects 0.000 description 11
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 10
- 229940118019 malondialdehyde Drugs 0.000 description 10
- 230000036542 oxidative stress Effects 0.000 description 10
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 9
- 108010012715 Superoxide dismutase Proteins 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 206010057430 Retinal injury Diseases 0.000 description 8
- 210000005252 bulbus oculi Anatomy 0.000 description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 description 7
- 102000007072 Nerve Growth Factors Human genes 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003900 neurotrophic factor Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000004792 oxidative damage Effects 0.000 description 5
- 230000008832 photodamage Effects 0.000 description 5
- 210000000608 photoreceptor cell Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 235000017784 Mespilus germanica Nutrition 0.000 description 3
- 244000182216 Mimusops elengi Species 0.000 description 3
- 235000000560 Mimusops elengi Nutrition 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 238000010802 RNA extraction kit Methods 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 235000007837 Vangueria infausta Nutrition 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000695 crystalline len Anatomy 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000012807 PCR reagent Substances 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- -1 decoction Substances 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000004662 cellular morphological change Effects 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000006667 mitochondrial pathway Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940073450 sudan red Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种抵御视网膜蓝光损伤的药食两用组合物及其制备方法和应用,它由下列重量份数的原料制成:枸杞子1~5份,茯苓2~6份,牡蛎4~8份,决明子2‑6份,菊花1~5份,铁皮石斛1~5份,叶黄素0.01~0.1份,牛磺酸0.01~0.1份。本发明提供的药食两用组合物,可抵御视网膜蓝光损伤,安全性好,可用于制备用于抵御视疲劳的普通食品或保健品或药品。
Description
技术领域
本发明涉及一种药食两用组合物,特别是涉及一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用。
背景技术
现代社会中,光污染对人的健康影响,越来越受到世人关注。光污染是继废气、废水、废渣和噪声等污染之后的一种新的环境污染源,主要包括白亮污染、人工白昼污染和彩光污染。其中,人类经历了5000多年的漫长进化,逐渐适应的由太阳以及由太阳引起的24小时昼夜交替和季节变化形成的“生物钟”,日出而作、日落而息的生活习惯,也因人工照明光源的出现而改变。虽然,工作时间得以延长,但是不健康的光照环境和作息的不规律违反了人体内长期形成的“生物钟”,使身体处于“亚健康”状态,出现失眠、免疫力下降、精神姜靡、内分泌失调等疾病。而最直接的影响,是对眼睛的影响。
光线穿过角膜、晶状体,映射到视网膜成像,形成视觉。人眼的晶状体承担着成像和保护视网膜的双重作用,有效隔绝了紫外线和红外线。但是,在可见光中,波长最短,光能量最大的蓝光,可直接穿过晶状体到达视网膜在眼底成像,对视网膜造成不可逆转的伤害,造成感光细胞与色素上皮细胞凋亡,轻则近视,严重的会导致眼部失明。
蓝光照射后,可能通过以下方式导致感光细胞凋亡:(1)视网膜ROS增加,细胞色素C增加,导致感光细胞内线粒体损伤,;(2)ROS诱导丝裂原蛋白活化激酶(MAPK)活化,下调细胞外调节蛋白激酶磷酸化(p-ERK)水平,诱导细胞死亡等过程;(3)上调活化的核转录因子(NF-KB),激活炎性通路,诱导细胞凋亡级联反应,导致视网膜感光细胞凋亡。
对于视网膜色素上皮细胞,蓝光照射后,可能通过以下方式导致感光细胞凋亡:(1)蓝光照射导致脂褐素在RPE细胞中大量累积,加速其主要荧光基团(A2E)对细胞的氧化,产生氧化应激反应,诱发细胞凋亡。(2)破坏细胞溶酶体功能。(3)跨膜电位变化蓝光可通过影响RPE细胞内Ca2+浓度,使线粒体跨膜电位发生变化,导致细胞凋亡。
从上述损伤机理可以发现,蓝光会导致感光细胞视或网膜色素上皮细胞损伤,该损伤是以光化学损伤为主,进而引起细胞的凋亡甚至死亡。其中线粒体途径引起的氧化应激反应及细胞凋亡在蓝光诱导的视网膜损伤中具有重要作用。
世界卫生组织早在2009年底,就发出橙色预警,认为蓝光辐射对人类的潜在威胁将远远超过苏丹红、三聚氰胺、SARS病毒等的破坏性,无形中吞噬人的双眼。中华医学会的统计数据显示,在中国4.2亿网民中,63.5%的人因蓝光辐射存在视力下降、白内障、失明等不同程度的眼疾。而随着科技的发展和生活、工作的需要,人们在智能手机、电脑、电视机上花费越来越多的时间。这些视频显示终端配备的液晶显示器,多采用发光二极管(LED)作为背光源,而LED中蓝光含量极高,对视网膜造成极大损害。因此,亟待采取相应措施,进行干预。
发明内容
发明目的:本发明的目的在于提供一种安全性好,具有抵御视网膜蓝光损伤作用的药食两用组合物。本发明的另一目的是提供上述组合物的制备方法和应用。
技术方案:为了实现以上目的,本发明采取的技术方案为:
一种具有抵御视网膜蓝光损伤的药食两用组合物,它包括下列重量份数的原料:枸杞子1~5份,茯苓2~6份,牡蛎4~8份,决明子2-6份,菊花1~5份,铁皮石斛1~5份,叶黄素0.01~0.1份,牛磺酸0.01~0.1份。
在此基础上形成的其较优配方为,它包括下列重量份数的原料:枸杞子2~4份,茯苓3~5份,牡蛎5~7份,决明子3-5份,菊花2~4份,铁皮石斛2~4份,叶黄素0.02~0.08份,牛磺酸0.02~0.08份。
进一步优化后得到的其最优配方为,它包括下列重量份数的原料:枸杞子3份,茯苓4份,牡蛎6份,决明子4份,菊花3份,铁皮石斛3份,叶黄素0.05份,牛磺酸0.05份。
本发明所述的具有抵御视网膜蓝光损伤与视疲劳的药食两用组合物的制备方法,包括以下步骤:
(1)按重量份数取枸杞子、茯苓、牡蛎,决明子、菊花、铁皮石斛、加入一定量的提取溶剂,回流提取,过滤;收集滤液。
(2)取步骤(1)中的药渣,加入一定量的提取溶剂,回流提取,过滤;收集滤液。
(3)取步骤(1)与(2)滤液,合并减压浓缩,加入叶黄素、牛磺酸,制得组合物。
作为优选方案,步骤(1)所述的回流提取条件为:首先加入药材重量10倍体积量的提取溶剂水,100℃回流提取120min。步骤(2)回流条件为:加入药材重量10倍体积量的提取溶剂水,100℃回流提取120min。
发明优势:本发明是基于中医药理论与蓝光损伤视网膜的病理机制,优选得到的抵御视网膜蓝光损伤的有效组合物。
中医学认为,眼与五脏六腑在生理、病理上均有着密切的关系。眼之所以能明视万物,辨别颜色,是赖五脏六腑精气血的濡养。在脏腑中,眼与肝、肾、脾的关系尤为密切。肝开窍于目,受肝血而能视物。肝气条达,血流方能调畅。脾主运化,运化水谷,为后天之本,精、气、血、津液生化之源,脾又主升清,才能将以上精微物质上输于目而使目得滋养,脾统血,才能使目中血液正常循行。肾主藏精,精充方能目明。肾又主津液水道,才能调节水液,上渗滋养目珠。因此,只有脏腑功能正常,才能保证精、气、血充盈,抵御外界伤害,从根本上解决视物障碍,视力损伤问题。
本药食两用组合物中,枸杞子滋肝补肾,益精明目;茯苓健脾利湿,通调水道,即可助脾健运化生水谷精微,又免湿聚眼底之患。牡蛎平肝潜阳,决明子清肝明目,菊花平肝明目,三者共用,避免肝阳上亢,将军之官得宁,气血畅达眼底。牡蛎又可软坚散结,若眼底有痰湿郁结,恰可消散。铁皮石斛为滋阴要药,避免阳亢所致阴虚。诸药共用,使目中精血充足,目视精明。
从组合物中药物的现代药理研究来看,枸杞子中玉米黄素可防止老年人黄斑色素减退和玻璃疣的积聚;多糖和类胡萝卜素成分有效保护视网膜色素上皮细胞氧化与炎性损伤;甜菜碱可抑制糖尿病患者视网膜新生血管形成。牡蛎所含的多种微量元素对于维持视力起着重要作用。菊花所含的芹菜素、木樨草素等黄酮类成分可保护视网膜色素上皮细胞免于氧化、炎症损伤,减少上述损伤引起的细胞凋亡,保护视网膜上皮色素细胞。铁皮石斛中的多糖成分具有降低视网膜及整体炎症因子的水平,抑制视网膜血管内皮因子(VEGF)表达,抑制新生血管生长。叶黄素可通过滤过可见光中引起光损伤的短波长光保护视网膜免受损伤,并且可以加强视锥细胞外节膜抗氧化损伤的功能,还可保护视网膜神经节细胞免受缺氧和氧化损伤。牛磺酸可通过改善膜通透性、抗脂质过氧化、提高抗氧化酶活性、抑制细胞凋亡等途径,保护视网膜抵御光损伤,发挥保护作用。
本发明提供的药食两用组合物,动物模型实验结果表明:本发明提供的药食两用组合物可有效抵御蓝光造成的视网膜损伤,降低高氧化应激水平这一蓝光损伤导致视网膜损伤的最主要病理环节,从而保护动物视网膜免收损伤。细胞模型实验结果表明,本发明提供的药食两用组合物可提高视网膜色素上皮细胞抵御氧化损伤能力,增加视网膜米勒细胞内神经营养因子的表达,从而达到抵御视网膜蓝光损伤的效果。
本发明所述的具有抵御视网膜蓝光损伤的药食两用组合物在眼部健康护理中的应用,将此药食两用组合物制备成食品或保健品或药品可接受的载体制成片剂、丸剂、散剂、汤剂、颗粒剂、煎膏剂或浸膏剂剂型的食品或保健品或药品,临床服用方便。尤其重要的是,该药食两用组合物所有组成药味与成分均为药食两用品种,安全性好,适合长期使用,可以起到抵御视网膜蓝光损伤的效果。
附图说明
图1为药食两用组合物对蓝光照射大鼠白箱停留时间影响的柱状图。
图2为药食两用组合物对蓝光照射大鼠视网膜组织影响的结构图。
图3为药食两用组合物对蓝光照射大鼠血清中ROS活性影响的柱状图。
图4为药食两用组合物对蓝光照射大鼠血清中MDA活性影响的柱状图。
图5为药食两用组合物对蓝光照射大鼠血清中SOD活性影响的柱状图。
图6为药食两用组合物对蓝光照射大鼠血清中GSH-Px活性影响的柱状图。
图7为药食两用组合物对蓝光照射大鼠血清中CAT活性影响的柱状图。
图8为药食两用组合物对蓝光照射损伤APRE-19细胞存活率影响的柱状图。
图9为药食两用组合物对Müller细胞中BBDNF表达影响的柱状图。
具体实施方式
下面结合具体实施例进一步阐明本发明,应理解这些实施例仅用于说明本发明而不用于限制本发明的范围,在阅读了本发明之后,本领域技术人员对本发明的各种等价形式的修改均落于本申请所附权利要求所限定的范围。
实施例1一种具有抵御视网膜蓝光损伤的药食两用组合物的制备方法,包括如下步骤:
(1)取枸杞子1份,茯苓2份,牡蛎3份,决明子2份,菊花1份,铁皮石斛1份,混合。加入药材重量8倍量的水回流提取120min,过滤,收集滤液和滤渣。
(2)取步骤(1)中的药渣,加入药材重量10倍体积量的水回流提取120min,过滤,收集滤液。
(3)合并步骤(1)与步骤(2)中所得滤液,减压浓缩得浸膏,加入叶黄素0.01份,牛磺酸0.01份,低温减压制得提取物。
实施例2一种具有抵御视网膜蓝光损伤的药食两用组合物的制备方法,包括如下步骤:
(1)取枸杞子2份,茯苓2份,牡蛎2份,决明子3份,菊花2份,铁皮石斛2份,混合。加入药材重量8倍量的水回流提取120min,过滤,收集滤液和滤渣。
(2)取步骤(1)中的药渣,加入药材重量10倍体积量的水回流提取120min,过滤,收集滤液。
(3)合并步骤(1)与步骤(2)中所得滤液,减压浓缩得浸膏,加入叶黄素0.08份,牛磺酸0.08份,低温减压制得提取物。
实施例3一种具有抵御视网膜蓝光损伤的药食两用组合物的制备方法,包括如下步骤:
(1)枸杞子3份,茯苓4份,牡蛎6份,决明子4份,菊花3份,铁皮石斛3份,混合。加入药材重量8倍量的水回流提取120min,过滤,收集滤液和滤渣。
(2)取步骤(1)中的药渣,加入药材重量10倍体积量的水回流提取120min,过滤,收集滤液。
(3)合并步骤(1)与步骤(2)中所得滤液,减压浓缩得浸膏,加入叶黄素0.05份,牛磺酸0.05份,低温减压制得提取物。
实施例4药食两用组合物抵御视网膜蓝光损伤动物实验研究
一、实验材料与药物
1.实验动物
SPF级雄性SD大鼠,体重180~220g,购自南京中医药大学实验动物中心,合格证号SCXK(苏)2015-0002。实验大鼠放置于南京中医药大学实验动物中心喂养,实验动物设施使用许可证SYXK(苏)2012-0047。
2.药物和试剂
过氧化氢酶(CAT)试剂盒、谷胱甘肽过氧化物酶(GSH-PX)试剂盒、活性氧(ROS)测试盒、超氧化物歧化酶(SOD)试剂盒、丙二醛(MDA)试剂盒(货号:A003-1)均购自南京建成生物工程研究所。TRIzol RNA提取试剂盒(15596-026,Invitrogen)。RT-PCR反转录试剂盒(PrimeScriptTM RT reagent Kit with gDNA Eraser,RR047A,TAKARA);SYBR荧光定量PCR试剂(FastStart Universal SYBR Green Master(ROX),04913914001,Roche)。Bradford试剂盒(T9310A,TAKARA)。
3.实验仪器
光照材料:卤素灯(飞利浦),蓝色干涉滤光片(波长450nrn,透过率34%,半宽度9nm,上海海光光学元件厂),电子温度计,医用铝箔纸,光照度计(上海光电研究所)。
光照箱:采用大小为1x 1x 1m3的立方形密闭木箱,内铺光滑漫反射材料(铝箔纸),箱的两侧有出气孔。用电子温度计监测箱内温度22~23℃。光照箱的侧面分别有一个直径为Zcm的小孔,用卤素灯透过波长为450nm的干涉滤光片,光线均透过侧面小孔进入,光照度计监测同一水平面的光照强度相同。
4.光照大鼠:大鼠实验前暗适应36小时,逐只放入光照箱中,接受蓝光连续照射60min后取出。对照组置于室内光线下。
二、实验方法
1.大鼠视网膜蓝光损伤模型的建立与药食两用组合物给药
健康大鼠适应性喂养5d后,随机分组:正常对照组(无蓝光照射)、模型对照组(蓝光照射)、给药组(蓝光照射+药物)。干预药物分别为每组8只动物,灌胃给药。正常对照组:正常饮食,正常饮水。模型对照组:蓝光照射,喂养3个月。给药组:实施例1、实施例2、实施例3,各分高剂量(8g/kg)、低剂量(4g/kg)两组。给予蓝光照射,同时给予实施例1~3的组合物高、低剂量,给药1个月。灌胃给药,每天下午2点开始灌胃,每周记录一次大鼠体重,每天早晚观察大鼠状态,及摄食和饮水情况。
2.大鼠视力评价
给药结束后,将大鼠放置在白箱的中央给予2700lux光照300s,拍摄记录小鼠在白箱中的行为,统计大鼠停留在白箱中的时间。
3.大鼠视网膜结构观察
将大鼠麻醉后打开胸腔,用50mL的注射器从心尖搏动最明显处进入左心室,剪开右心耳,体内缓慢灌注PBS与4%多聚甲醛(PFA)各50mL,进行体内固定;快速取眼球,角膜穿刺,放入固定液中固定0.5-1.0h,然后去除眼前节;将去除眼前节的眼球在原固定液中继续固定24h。
先对固定后的眼球壁脱水,脱水后透明,将透明的大鼠眼球壁放入蜡缸中浸蜡,包埋蜡块后切片,每张片子厚度为5μm。
HE染色观察视网膜结构与细胞形态变化,40x10倍光学显微镜下测量视网膜石蜡切片HE染色后外核层厚度,选择视网膜损伤最重处进行测量。
3.大鼠血清中SOD、GSH-Px、CAT活性和ROS、MDA含量测定
观察期满,处死动物,摘取眼球,眼周围静脉取血,3000rpm,4℃离心10min,分离血清,-20度保存备用。分别按照SOD、GSH-Px、CAT、ROS、MDA试剂盒说明书测定血清中SOD、GSH-Px、CAT活性和ROS、MDA含量。
4.统计学处理
三、实验结果
1.药食两用组合物保护蓝光照射大鼠的视力。
结果如图1显示,与正常组相比,蓝光照射的模型组小鼠在白箱中的停留时间更长(P<0.01),说明蓝光照射导致模型组小鼠视力严重受损。与模型组相比,实施例1至3的药食两用组合物组的小鼠,在白箱中的停留时间显著缩短,能更快找到黑箱入口,表明3个实施例的药食两用组合物均对蓝光照射导致的视力损伤具有保护作用。并且经过对比,3个实施例中,以最优方案实施例3效果最好。
2.视网膜结构与细胞形态变化
HE染色观察。如图2A所示,正常对照组大鼠视网膜结构层次分明,视网膜内外节排列整齐,外核层细胞核层次清楚,排列紧密,染色均匀,形态规则,视网膜其它各层分界清楚。图2B显示,模型对照组视网膜外核层厚度明显变薄,且细胞核皱缩,细胞排列紊乱,外核层与外丛状层界限不清。3个实施例的高剂量组大鼠,与模型对照组比较,视网膜结构排列较整齐,外核层厚度明显增加,其中以图2中E所示的实施例3高剂量给药组最为接近正常组。
3.药食两用组合物显著降低大鼠血清中氧化应激水平
如图3-图4所示,与正常对照组相比,模型对照组大鼠血清中总活性氧(ROS)水平明显提高(P<0.01),表明模型大鼠体内存在高水平的氧化应激;同时模型组中的脂质过氧化物丙二醛(MDA)含量也显著升高(P<0.01),表明蓝光照射的大鼠眼球后静脉血中存在高水平的氧化应激(P<0.01)。
经实施例1至3三种不同配比的药食两用组合物灌胃治疗后,与模型对照组相比,低、高剂量组大鼠血清中总ROS水平均明显降低,血清中MDA含量亦显著降低(P<0.01),说明药食两用组合物可以降低血清中总ROS和MDA的含量,可以改善模型大鼠视网膜的氧化应激状态,减少活性氧及各种氧自由基对大鼠视网膜的损伤。且经过对比,三种不同配比的药食两用组合物中,以实施例3的最优配比降低氧化应激水平最好。
4.药食两用组合物显著提升大鼠体内抗氧化应激酶水平
如图5-图7所示,与正常对照组比较,蓝光照射的模型大鼠血清中,超氧化物歧化酶(SOD)活性明显降低(P<0.01),同时血清中谷胱甘肽过氧化物酶(GSH-PX)活性也显著降低(P<0.01),提示模型大鼠体内由于存在较高水平的氧化损伤,导致抗氧化应激因子水平下降。同时模型组大鼠血清中过氧化氢酶(CAT)活性显著下降(P<0.01),由于CAT为氢氧自由基(OH-)的水解酶,CAT活性下降,会导致氧自由基水平相对升高,提示模型大鼠体内存在氧化应激状态。对大鼠视网膜组织造成较强氧化损伤。
与模型对照组比较,药食两用组合物三个实施例均可以明显提高蓝光照射大鼠血清中SOD、GSH-Px、CAT的活性,各组合物的高剂量组均优于低剂量组。其中以实施例3最优配比的效果最显著(P<0.01),提示药食两用组合物可以提高蓝光照射大鼠视网膜血清中抗氧化酶的活性,并具有剂量依赖性,发挥抗氧化作用,从而改善视网膜的氧化应激状态,抵御视网膜蓝光照射损伤
实施例5药食两用组合物抗视网膜色素上皮细胞(ARPE-19)蓝光照射损伤
一、实验材料与药物
1.细胞
人视网膜上皮色素细胞(ARPE-19)购自ATCC,存于江苏省中药资源产业化过程协同创新中心。
2.实验仪器
二氧化碳培养箱(Forma series Ⅱ water jacket CO2 incubator,Thermo公司),1300series A2超净工作台(Thermo公司),Auto VertA1倒置荧光显微镜(ZEISS公司),Nanodrop(DS11spectrophotometer,DeNovix公司),ABI7500荧光实时定量PCR仪(Invitrogen公司),高速离心机(Allegra X-12R Centrifuge和Microfuge 22RCentrifuge,Backman公司),恒温水浴锅(Bluepard公司),恒温振荡器(IS-RDV1 incubatorshaker,CRYSTAL公司),细胞培养器皿(CORNING公司)。光照箱(同实施例4)
3.试剂
无水乙醇(分析纯)、H2O2溶液(分析纯)均购自国药上海公司。DMEM/F12培养基、10%胎牛血清(FBS)、1%双抗(青霉素和链霉素,P/S)购自Biological Industries公司。细胞培养所用的耗材均购自Corning公司。TNF-α购自Novel Protein公司。其他未特别注明的试剂,均购自Sigma-Aldrich公司。
二、实验方法
1.细胞培养与给药
ARPE-19细胞为人视网膜色素上皮细胞,培养基为DMEM/F12,并在其中加入10%FBS和1%P/S。将冻存于液氮罐中的ARPE-19细胞在37℃水浴复苏,置于60mm培养皿中培养。每48h换液1次,观察细胞密度,当达到85%时,吹打传代,使每个60mm培养皿中细胞数为1X105。当细胞传代三次后,生长稳定,将细胞按浓度5×103个/孔,接种于96孔板中,每孔的培养体积为100μL,给药3小时前更换新的培养基。实施例1~3各药食两用组合物分为高(10μg/mL)、低(3μg/mL)两个剂量进行给药,给药48h。
药食两用组合物培养细胞48小时后,置于光照箱中,给予蓝光照射1h。
2.MTT检测
将ARPE-19细胞加以药食两用组合物与培养48h后,置于光照箱中,给予蓝光照射1h。然后加入MTT(5mg/mL)10μL。在培养箱内培养3小时,用移液枪吸去培养液,每孔加入150μL二甲基亚砜,置摇床上室温低速震荡30min,使结晶物充分溶解,并在酶联免疫检测仪OD570 nm处测量各孔的吸光值(A570)。计算每组细胞存活率,存活率(%)=A(实验组)/A(对照组)×100%。每个实验平行操作三次。
3.统计学处理
三、实验结果
将体外培养的ARPE-19细胞,加以不同比例的药食两用组合物48h后,利用蓝光照射构建损伤模型,利用MTT法检测细胞存活率。如图8所示,实施例1~3各药食两用组合物可以显著保护ARPE-19细胞免受过氧化氢损伤,其中实施例3保护效果最为显著。
实施例6药食两用组合物促进视网膜米勒细胞神经营养因子表达
一、实验材料与药物
1.细胞
米勒细胞(Müller)购自ATCC,存于江苏省中药资源产业化过程协同创新中心。
2.实验仪器
二氧化碳培养箱(Forma series Ⅱ water jacket CO2 incubator,Thermo公司),1300series A2超净工作台(Thermo公司),Auto VertA1倒置荧光显微镜(ZEISS公司),Nanodrop(DS11spectrophotometer,DeNovix公司),ABI7500荧光实时定量PCR仪(Invitrogen公司),高速离心机(Allegra X-12R Centrifuge和Microfuge 22RCentrifuge,Backman公司),恒温水浴锅(Bluepard公司),恒温振荡器(IS-RDV1 incubatorshaker,CRYSTAL公司),细胞培养器皿(CORNING公司)。
3.试剂
TRIzol RNA提取试剂盒(15596-026,Invitrogen)。RT-PCR反转录试剂盒(PrimeScriptTM RT reagent Kit with gDNA Eraser,RR047A,TAKARA);SYBR荧光定量PCR试剂(FastStart Universal SYBR Green Master(ROX),04913914001,Roche)。Bradford试剂盒(T9310A,TAKARA)。
二、实验方法
1.细胞培养与给药
Müller细胞为人视网膜米勒细胞,培养基为DMEM,并在其中加入10%FBS和1%P/S。将冻存于液氮罐中的Müller细胞在37℃水浴复苏,置于60mm培养皿中培养。每48h换液1次,观察细胞密度,当达到85%时,吹打传代,使每个60mm培养皿中细胞数为,以1×106/皿的细胞密度接种于直径为60mm的培养皿中。
待培养皿中的细胞长至汇合度为90%时,给以实施例1~3的药食两用组合物高(10μg/mL)、低(3μg/mL)两个剂量组,阳性药cAMP(50μM),培养24h。
2.实时定量荧光PCR仪测定神经营养因子转录水平表达
RNA提取:吸去细胞培养液,加入2mL的PBS冲洗,每盘细胞中加入500μL的TRIzol,按TRIzol RNA提取试剂盒所列步骤进行操作。所提取RNA于-80℃保存。
cDNA的制备:用Nanodrop测试RNA的浓度和纯度,根据TaKaRa逆转录试剂盒的说明,总计取用1μg的RNA来进行逆转录的操作。
依照SYBR荧光实时定量试剂盒操作步骤,利用荧光实时定量PCR仪测定神经营养因子的基因转录水平表达。所用引物序列如下:
表2引物序列
3.统计学处理
三、实验结果
视网膜米勒细胞可提供神经营养因子,维持视网膜神经节细胞的正常生长。将体外培养的人视网膜米勒细胞,加以不同比例的药食两用组合物24h后,利用qPCR技术检测细胞内神经营养因子BDNF的表达。如图9所示,实施中各药食两用组合物可以显著促进人视网膜米勒细胞内BDNF的表达,表现出较好的神经营养活性。
本发明提供的药食两用组合物,动物模型实验结果表明:本发明提供的药食两用组合物可有效降低高氧化应激水平这一导致视网膜蓝光损伤的最主要病理环节,从而保护动物视网膜免收损伤。细胞模型实验结果表明,本发明提供的药食两用组合物可提高视网膜色素上皮细胞抵御氧化损伤能力,增加视网膜米勒细胞内神经营养因子的表达,从而达到保护视网膜损伤的效果。
以上实验结果表明,本发明提供的药食两用组合物具有显著的对抗蓝光照射所致的视网膜损伤功能。该组合物不仅能提高视网膜色素上皮细胞抵御氧化损伤能力,还能增加视网膜米勒细胞内神经营养因子的表达作用,从而达到保护视网膜损伤的效果,具有多靶点的作用特点。尤其重要的是,该药食两用组合物所有组成药味与成分均为药食两用品种,安全性好,适合长期使用,可以起到抵御蓝光照射损伤,保护视力的效果。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (6)
1.一种具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,它包括下列重量份数的原料:枸杞子1~5份,茯苓2~6份,牡蛎4~8份,决明子2-6份,菊花1~5份,铁皮石斛1~5份,叶黄素0.01~0.1份,牛磺酸0.01~0.1份。
2.根据权利要求1所述的一种具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,它包括下列重量份数的原料:枸杞子2~4份,茯苓3~5份,牡蛎5~7份,决明子3-5份,菊花2~4份,铁皮石斛2~4份,叶黄素0.02~0.08份,牛磺酸0.02~0.08份。
3.根据权利要求1所述的具有抵御视网膜蓝光损伤的药食两用组合物,其特征在于,它包括下列重量份数的原料:枸杞子3份,茯苓4份,牡蛎6份,决明子4份,菊花3份,铁皮石斛3份,叶黄素0.05份,牛磺酸0.05份。
4.权利要求1~3任一项所述的具有抵御视网膜蓝光损伤的药食两用组合物的制备方法,其特征在于,它包括以下步骤:
(1)按重量份数取枸杞子、菊花、铁皮石斛、决明子、茯苓、牡蛎,加入5~15倍量的水,回流提取1~2h,过滤;收集滤液;
(2)取步骤(1)中的药渣,加入5~15倍量的水,回流提取1~2h,过滤;收集滤液;
(3)取步骤(1)与(2)滤液,合并减压浓缩,加入叶黄素、牛磺酸,制得组合物。
5.权利要求1至3任一项所述的具有抵御视网膜蓝光损伤的药食两用组合物在制备抵御视网膜蓝光损伤的食品或保健品或药品中的应用。
6.根据权利要求5所述的应用,其特征在于,将组合物的提取物和食品及药学上可接受的载体制成口服液、软糖、片剂、汤剂、颗粒剂、煎膏剂或浸膏剂的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010569690.8A CN111686208B (zh) | 2020-06-20 | 2020-06-20 | 具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010569690.8A CN111686208B (zh) | 2020-06-20 | 2020-06-20 | 具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111686208A true CN111686208A (zh) | 2020-09-22 |
CN111686208B CN111686208B (zh) | 2022-03-11 |
Family
ID=72482553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010569690.8A Active CN111686208B (zh) | 2020-06-20 | 2020-06-20 | 具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111686208B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116139235A (zh) * | 2021-11-19 | 2023-05-23 | 宁夏枸杞创新中心(有限公司) | 一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法与应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103734712A (zh) * | 2013-12-02 | 2014-04-23 | 中国农业大学 | 一种护眼蓝莓和树莓功能食品 |
CN105192696A (zh) * | 2015-08-17 | 2015-12-30 | 北京元莱健康管理有限公司 | 一种保护眼底、营养视网膜及抵御蓝光损伤的组合物及其制备方法 |
CN105505727A (zh) * | 2016-01-31 | 2016-04-20 | 甘秋金 | 一种明目提神的醋饮 |
CN106942532A (zh) * | 2016-01-07 | 2017-07-14 | 吕学栋 | 一种具有保护视力效果的饮料 |
CN107156839A (zh) * | 2017-05-19 | 2017-09-15 | 内蒙古医科大学 | 一种护眼保健食品及其制备方法 |
CN109770364A (zh) * | 2019-03-07 | 2019-05-21 | 通化禾韵现代农业股份有限公司 | 具有缓解视疲劳功能的组合物、制备方法及应用 |
-
2020
- 2020-06-20 CN CN202010569690.8A patent/CN111686208B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103734712A (zh) * | 2013-12-02 | 2014-04-23 | 中国农业大学 | 一种护眼蓝莓和树莓功能食品 |
CN105192696A (zh) * | 2015-08-17 | 2015-12-30 | 北京元莱健康管理有限公司 | 一种保护眼底、营养视网膜及抵御蓝光损伤的组合物及其制备方法 |
CN106942532A (zh) * | 2016-01-07 | 2017-07-14 | 吕学栋 | 一种具有保护视力效果的饮料 |
CN105505727A (zh) * | 2016-01-31 | 2016-04-20 | 甘秋金 | 一种明目提神的醋饮 |
CN107156839A (zh) * | 2017-05-19 | 2017-09-15 | 内蒙古医科大学 | 一种护眼保健食品及其制备方法 |
CN109770364A (zh) * | 2019-03-07 | 2019-05-21 | 通化禾韵现代农业股份有限公司 | 具有缓解视疲劳功能的组合物、制备方法及应用 |
Non-Patent Citations (1)
Title |
---|
汪明芳等: "叶黄素对大鼠视网膜蓝光光损伤的保护作用", 《卫生研究》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116139235A (zh) * | 2021-11-19 | 2023-05-23 | 宁夏枸杞创新中心(有限公司) | 一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法与应用 |
CN116139235B (zh) * | 2021-11-19 | 2023-11-21 | 宁夏枸杞创新中心(有限公司) | 一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111686208B (zh) | 2022-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ouyang et al. | Mechanisms of blue light-induced eye hazard and protective measures: a review | |
CN105368622A (zh) | 精选原料简化工艺生产植物生物抗氧化剂营养增强葡萄酒 | |
CN102225087A (zh) | 一种强效护眼的叶黄素复方制剂 | |
CN104147081A (zh) | 改善视力的蓝莓叶黄素软胶囊及制作方法 | |
Mahendra et al. | Detrimental effects of UVB on retinal pigment epithelial cells and its role in age-related macular degeneration | |
CN103860625A (zh) | 越橘提取物眼用制剂及其制备方法和用途 | |
JP7377283B2 (ja) | 人の目の水晶体及び網膜感光細胞栄養素が含まれる、目を保護し視力を良くする生薬菓子の製造方法 | |
CN109663122A (zh) | 一种为视网膜黄斑区提供营养、改善视力、预防眼病的组合物颗粒冲剂及其制备方法 | |
CN103300373A (zh) | 叶黄素原花青素复合软胶囊及其制备方法 | |
JP2022024039A (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
CN111686208B (zh) | 具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 | |
CN111528421A (zh) | 含有植物外泌体的护眼产品及其制备方法 | |
EP3949971A1 (en) | Use of luteolin-7-o-glucoside or luteolin-7-o-glucuronide in preparation of medicine for eye injuries | |
CN101019914A (zh) | 一种含叶黄素的软胶囊及其制备方法 | |
CN111658740B (zh) | 具有改善年龄相关性黄斑变性的药食两用组合物及其制备方法与应用 | |
EP3570862B1 (en) | Compositions based on active principles of plants origin having eye protection action | |
CN103070877A (zh) | 一种视力保健药物 | |
CN103039968A (zh) | 一种保护视力保健品的配方及其制备方法 | |
KR101769987B1 (ko) | 스피루리나 추출물을 유효성분으로 함유하는 망막질환 예방 및 치료용 약학적 조성물 | |
JP2017165766A (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
Thiagarajan et al. | Approaches to relieve the burden of cataract blindness through natural antioxidants: use of Ashwagandha (Withania somnifera) | |
CN115487221A (zh) | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 | |
CN108685961B (zh) | 一种改善学习记忆组合物及制剂,其制备方法及应用 | |
CN109078083B (zh) | 黑西红柿萃取物降低眼压、减少蓝光所致视网膜损伤、及提升眼睛调节灵活度的用途 | |
CN112843155B (zh) | 一种适合产妇用的祛斑及缓解腰痛的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |